Maxadilan interacts with receptors for pituitary adenylyl cyclase activating peptide in human SH-SY5Y and SK-N-MC neuroblastoma cells

Neuropeptides

Volumn 33, Issue 2, 1999, Pages 107-114

  Eggenberger, M ^a   Born, W ^a   Zimmermann, U ^a   Lerner, E A ^b   Fischer, J A ^a   Muff, R ^a,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CALCIUM; CYCLIC AMP; MAXADILAN; POLYPEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MYOBLAST; NEUROBLASTOMA; PRIORITY JOURNAL; RECEPTOR BINDING;

LUTZOMYIA LONGIPALPIS; PHLEBOTOMINAE;

EID: 0033120143     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1054/npep.1999.0004     Document Type: Article

References (27)

1. Lerner EA, Ribeiro JM, Nelson RJ, Lerner MR. Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand fly Lutzomyia longipalpis. J Biol Chem 1991; 266: 11234-11236.
2. Ribeiro JM, Vachereau A, Modi GB, Tesh RB. A novel vasodilatory peptide from the salivary glands of the sand fly Lutzomyia longipalpis. Science 1989; 243: 212-214.
3. Taitus RG, Ribeiro JMC. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988; 239: 1306-1308.
4. Grevelink SA, Osborne J, Loscalzo J, Lerner EA. Vasorelaxant and second messenger effects of maxadilan. J Pharmacol Exp Therap 1995; 272: 33-37.
5. Jackson TS, Lerner EA, Weisbrod RM, Tajima M, Loscalzo J, Keaney JF. Vasodilatory properties of recombinant maxadilan. Am J Physiol 1996; 271: H924-H930.
6. Qureshi AA, ASahina A, Ohnuma M, Tajima M, Granstein RD, Lerner EA. Immunomodulatory properties of maxadilan, the vasodilator peptide from and fly salivary gland extracts. Am J Trop Med Hyg 1996; 54: 665-671.
7. Lerner EA, Shoemaker CB. Maxadilan. Cloning and functional expression of the gene encoding this potent vasodilator peptide. J Biol Chem 1992; 267: 1062-1066.
8. Yoshida S, TAkamatsu T, Denda S et al. Structural characterization and localization of disulphide linkages of a potent vasodilatory peptide, recombinant maxadilan, by a multiple mass spectrometric approach. Rapid Commun Mass Spectrometry 1996; 10: 641-648.
9. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982; 298: 240-244.
10. Nong YH, Titus RG, Ribeiro JM, Remold HG. Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol 1989; 143: 45-49.
11. Tippins JR. CGRP: A novel neuropeptide from the calcitonin gene is the most potent vasodilator known. J Hypertens Suppl 1986; 4: S102-S105.
12. Brain SD, Tippins JR, Morris HR, MacIntyre I, Williams TJ. Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol 1986; 87: 533-536.
13. Moro O, Tajima M, Lerner EA. Receptors for the vasodilator maxadilan are expressed on selected neural crest and smooth muscle-derived cells. Insect Biochem Molec Biol 1996; 26: 1019-1025.
14. Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: Neuroendocrine and endocrine interaction. Front Neuroendocrinol 1995; 16: 53-88.
15. Moro O, Tsomides TJ, Tajima M, Lerner EA. Maxadilan binds to membrane fractions of brain tissue. Biochem Biophys Res Commun 1995; 216: 234-241.
16. Miyata A, Jiang L, Dahl RD et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 1990; 170: 643-648.
17. Robberecht P, Gourlet P. Recombinant receptors for testing agonist and antagonists of VIP and PACAP receptors. J Pharm Belg 1996; 51: 165-169.
18. Moro O, Lerner EA. Maxadilan, the vasodilator from sandflies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J Biol Chem 1997; 272: 966-970.
19. Harmar AJ, Arimura A, Gozes I et al. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50: 265-270.
20. Ohnuma M, Denda S, Ehama R et al. Peptide Chemistry 1993. Osaka: Protein Research Foundation. 1994; 145-148.
21. Hunter WM, Greenwood FC. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 1962; 194: 495-498.
22. Hussain AA, Jona JA, Yamada A, Dittert LW. Chloramine-t in radiolabeling techniques. Anal Biochem 1995; 224: 221-226.
23. Eggenberger M, Flühmann B, Muff R et al. Structure of a parathyroid hormone/parathyroid hormone-related peptide receptor of the human cerebellum and functional expression in human neuroblastoma SK-N-MC cells. Mol Brain Res 1996; 36: 127-136.
24. Robberecht P, Gourlet P, De Neef P et al. Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Eur J Biochem 1992; 207: 239-246.
25. i and inositol phosphates in human neuroblastoma NB-OK-1 cells. Peptides 1993; 14: 1111-1118.
26. Waschek JA, Richards ML, Bravo DT. Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines. Cancer Lett 1995; 92: 143-149.
27. Svoboda M, Tastenoy M, Rampelbergh JV et al. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 1994; 205: 1617-1624.